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Abstract  Multiple  myeloma  (MM)  is  a  malignant  haematological  disease  characterised  by
clonal proliferation  of  malignant  plasma  cells  in  the  bone  marrow.  MM  is  expressed  by  diffuse
inﬁltration  of  the  bone  marrow,  focal  bone  lesions  and  extra-medullary  lesions.  Conventional
staging follows  the  Salmon  and  Durie  classiﬁcation,  which  was  recently  revised  (Salmon  and
Durie plus)  to  include  MRI  and  FDG-PET  examinations.  FDG-PET  is  being  evaluated  for  initial
staging and  therapeutic  monitoring  and  its  place  still  needs  to  be  validated,  particularly  in
comparison  with  MRI  of  the  pelvis  and  spine,  the  reference  examination  for  diagnosis,  which
is systematically  combined  with  X-rays  of  the  skeleton.  Certain  recent  data  in  the  literature
suggest that  FDG-PET  provides  better  staging  of  the  disease  at  the  time  of  diagnosis  than  MRI,
and that  the  examination  has  considerable  prognostic  value  when  it  normalises  after  the  initial
courses of  chemotherapy  and  at  the  end  of  treatment.  As  for  the  evaluation  of  lymphomas,  the
interpretation  criteria  should  be  standardised.
© 2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Positron  emission  tomography  using  ﬂuorine-18  labelled  ﬂuorodeoxyglucose  (FDG-PET)
is  a  three-dimensional  non-invasive  whole  body  imaging  technique  providing  excellent
diagnostic  performance  in  terms  of  sensitivity  and  resolution.  The  technique  has  been
validated  in  recent  years  in  numerous  oncological  indications,  for  initial,  end  of  treatment
or  early  therapeutic  evaluation  of  various  solid  tumours  (bronchial,  ENT  and  colorectal
carcinomas,  melanomas  etc.)  or  haematological  diseases  (diffuse  large  B-cell  lymphoma
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ated  with  event-free  survival,  but  not  with  overall  survival
[13].FDG-PET  in  the  evaluation  of  myeloma  in  2012  
or  Hodgkin’s  disease)  [1,2]. Semi-quantitative  study  of  the
consumption  of  FDG  by  determining  the  standardised  uptake
value  (SUV)  may  have  prognostic  value  in  certain  diseases
(bronchial  carcinomas,  lymphomas)  [3].
Multiple  myeloma  (MM)  is  a  malignant  haematological  dis-
ease  characterised  by  the  clonal  proliferation  of  malignant
plasma  cells  in  the  bone  marrow.  It  is  expressed  by  diffuse
inﬁltration  of  the  bone  marrow,  focal  bone  lesions  and  extra-
medullary  lesions  (EML).  Conventional  staging  follows  the
Salmon  and  Durie  classiﬁcation,  initially  described  in  1975,
which  was  recently  revised  (the  Salmon  and  Durie  plus  clas-
siﬁcation)  to  include  MRI  and  FDG-PET  results  [4,5]. FDG-PET
is  being  evaluated  for  initial  staging  and  therapeutic  moni-
toring  of  patients  with  multiple  myeloma  (MM),  and  its  place
still  needs  to  be  validated,  particularly  in  comparison  with
MRI  of  the  pelvis  and  spine,  the  current  reference  exami-
nation  for  diagnosis  systematically  combined  with  X-rays  of
the  skeleton  [6].  Certain  recent  data  in  the  literature  nev-
ertheless  suggest  that  FDG-PET  provides  better  staging  of
the  disease  at  the  time  of  diagnosis  than  MRI  and  that  the
examination  has  considerable  prognostic  value  when  it  nor-
malises  after  the  initial  courses  of  chemotherapy  and  at  the
end  of  treatment.  As  for  the  evaluation  of  lymphomas,  the
interpretation  criteria  must  be  standardised  for  FDG-PET  to
be  used  in  the  routine  evaluation  of  MM.
FDG-PET and initial staging
The  clinical  symptoms  of  MM  are  a  combination  of  anaemia,
hypercalcaemia,  renal  impairment,  and  above  all  multi-
ple  bone  lesions,  which  are  present  in  80%  of  symptomatic
patients.  At  the  time  of  diagnosis,  it  is  indispensable  to
evaluate  these  bone  lesions  by  imaging  techniques.  In  addi-
tion  to  exploring  the  whole  body  using  standard  X-rays,  an
MRI  of  the  pelvis  and  spine  is  the  reference  examination
for  detecting  both  focal  lesions  (FL)  and  diffuse  lesions  of
the  disease  [4—6]. Classic  imaging  shows  one  or  more  visi-
ble  focal  osteolytic  lesions  on  standard  X-rays,  but  systemic
bone  loss  with  the  appearance  of  osteoporosis  may  also  be
found  [7].  There  are  also  very  rare  forms  of  osteosclerotic
myeloma  (POEMS  syndrome:  Polyneuropathy,  Organomegaly,
Endocrinopathy,  Monoclonal  gammapathy,  and  Skin  lesions)
which  appear  as  diffuse  or  localised  bone  condensation.  A
minority  of  patients  appear  normal  in  imaging.  Diffuse  inﬁl-
tration  of  the  marrow  by  MM  cells  is  often  accompanied  by
FL,  with  or  without  osteolysis.  These  well  delimited  FL  are
shown  by  hyperﬁxation  in  a  FDG-PET  scan  or  an  abnormal  MRI
signal.  To  avoid  false-positives,  only  abnormalities  of  at  least
5  mm  diameter  should  be  considered  as  focal  lesions  [8].  At
the  time  of  diagnosis,  about  5%  of  patients  are  considered
as  having  a  solitary  plasmacytoma  (SP)  of  the  soft  tissues
or  bones,  most  of  whom  have  under-staged  MM.  Additional
bone  marrow  biopsy,  MRI  or  FDG-PET  examinations  often  re-
establish  a  diagnosis  of  MM  by  showing  other  sites  of  disease
[9—11].  Correct  diagnosis  is  essential  for  deciding  on  appro-
priate  treatment;  patients  with  SP  rarely  require  systemic
treatment  [12].The sensitivity  of  MRI  is  approximately  70%  in  MM  and  the
number  of  lesions  detected  by  MRI  on  diagnosis  is  an  inde-
pendent  prognostic  factor  of  survival,  as  was  shown  by  the
largest  series  in  the  literature  published  in  2007  concerning
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11  patients  treated  in  a  uniform  manner  [13]. FDG-PET  has
een  studied  in  MM  more  recently,  but  in  2010,  international
xperts  did  not  recommend  its  routine  use  for  initial  or  pro-
nostic  evaluation  of  the  disease  [6].  Nevertheless,  there
re  strong  data  in  support  of  its  use.  Since  with  FDG-PET,  the
hole  body  and  skeleton  can  be  explored,  its  sensitivity  is  in
he  order  of  90%  for  detecting  myelomatous  lesions  [14—18],
nd  it  shows  focal,  diffuse  or  mixed  lesions  with  variable
lucose  uptake  giving  variable  SUVmax  values  (Fig.  1).  PET
ombined  with  CT  has  shown  itself  to  be  superior  to  PET
lone,  since  analysis  of  the  CT  slices  improves  the  detection
f  bone  lesions  [13,18].
The  sensitivity  of  FDG-PET  is  greater  than  whole  body
-ray  examinations:  the  technique  shows  additional  lesions
n  half  the  patients  but  false  negatives  for  small  lesions
etected  by  standard  X-rays  [14]. Small  series  have  com-
ared  the  sensitivity  of  FDG-PET  with  pelvic  and  spinal
RI  [14,15]. The  sensitivity  of  FDG-PET  was  comparable
o  or  less  than  that  of  the  MRI  for  diffuse  spinal  lesions
ut  detected  additional  FLs.  Moreover,  FDG-PET  detected
dditional  bone  marrow  or  extra-medullary  lesions  in  the
egions  not  explored  by  the  MRI.  In  patients  with  SP,  FDG-PET
etected  additional  lesions,  with  sensitivity  and  speciﬁcity
igher  than  that  of  MRI  (Figs.  2  and  3).
A  large  series  concerning  239  patients,  given  uniform
rst  line  treatment  in  the  ‘‘total  therapy’’  double  autol-
gous  transplantation  programme  of  the  group  in  Little
ock,  Arkansas,  prospectively  compared  FDG-PET  and  MRI
or  assessing  the  respective  prognostic  value  of  these  exam-
nations  [16]. In  multivariate  analysis,  the  only  imaging
xamination  signiﬁcantly  associated  with  poor  prognosis
oth  for  survival  and  for  event-free  survival  when  the  num-
er  of  FL  was  greater  than  3  on  diagnosis,  was  FDG-PET.  The
umber  of  FL  on  the  initial  MRI  (seven  or  more)  was  associ-igure 1. FDG-PET in a patient with multiple myeloma: increase
n diffuse bone marrow uptake associated with focal lesions.
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aigure 2. FDG-PET in a patient with solitary sacral plasmacytoma
The  prognostic  value  of  the  number  of  FLs  on  the  initial
DG-PET  was  conﬁrmed  in  another  recent  large  series  of  192
atients  with  MM  in  a  double  autologous  transplantation  pro-
ramme  following  induction  consisting  of  thalidomide  and
examethasone  [16]. In  this  study,  having  at  least  three  FL
44%  of  cases),  an  SUV  >  4.2  (46%  of  cases),  and  the  presence
f  EMLs  (6%)  negatively  affected  progression-free  survival
t  4  years.  An  SUV  >  4.2  and  the  presence  of  EMLs  were
lso  associated  with  shorter  overall  survival.  It  is  known
hat  EMLs  are  associated  with  poorer  prognosis,  above  all  if
hey  are  present  in  the  initial  staging  [19]. Fig.  4  illustrates
he  case  of  a  patient  explored  during  initial  pre-therapeutic
taging  of  MM:  PET  detected  EMLs  and  the  SUV  was  measured
s  22.4  on  the  skeleton,  indicating  the  aggressiveness  of  the
isease.  The  more  prolonged  the  evolution  of  the  disease,
he  more  likely  it  is  that  low  or  non-secreting  disease  will
s
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aevelop,  both  of  which  are  high  risk  for  poor  differentiation
nd  aggressiveness.
FDG-PET  is  also  very  useful  for  evaluating  the  rare  non-
r  low-secreting  forms  of  MM,  which  cannot  be  evaluated  by
aboratory  methods.
DG-PET and therapeutic evaluation
s  for  malignant  lymphoma,  obtaining  complete  metabolic
emission  (CMR)  in  an  intermediate  evaluation  before  or
fter  autologous  transplantation  is  associated  with  better
urvival.  In  2009,  Bartel  et  al.  showed  that  normalisa-
ion  of  FDG  ﬁxation  in  focal  lesions  of  bone  and  the
ites  of  EMLs  after  the  initial  course  of  chemotherapy
nd  before  autologous  transplantation  was  associated  with
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Figure 3. FDG-PET in a patient with solitary nasopharyngeal plasmacytoma.
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ibetter  event-free  survival  and  overall  survival  [19]. When
compared  with  the  genetic  proﬁles,  CMR  before  autologous
transplantation  seemed  to  indicate  better  overall  survival
in  low  risk  patients  and  better  event-free  survival  in  high-
risk  patients.  In  Zamagni’s  series,  the  persistence  of  an
SUV  >  4.2  after  induction  of  therapy  was  associated  with
lower  progression-free  survival  [17]. Three  months  after
the  autologous  transplant,  CMR  was  obtained  in  65%  of
patients,  with  PFS  and  overall  survival  at  4  years  higher
than  that  of  PET-positive  patients.  Interestingly,  23%  of
n
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t
natients  obtaining  CR  according  to  conventional  criteria
ere  considered  to  be  PET-positive.  Multivariate  analysis
howed  that  the  PET  status  after  autologous  transplantation
as  an  independent  prognostic  factor  for  progression-
ree  survival.  Following  this  publication,  in  an  editorial
n  Blood  in  2011,  Moreau  discussed  the  possibility  of  a
ew  deﬁnition  of  CR  in  patients  being  monitored  for  MM,
ntegrating  the  data  from  metabolic  imaging  [18]. Addi-
ional  studies  and  standardised  interpreting  criteria  will  be
ecessary.
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Figure 4. FDG-PET in a patient with multiple myeloma: diffuse bone marrow hypermetabolism (a) with lytic lesions extending to the soft
tissue (b), splenic (c) and lymph node involvement (d).
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Conclusion
Even  if  it  is  still  not  validated  for  routine  clinical  use,
FDG-PET  seems  to  be  a  promising  imaging  technique  for
evaluating  MM  and  SP.  Recent  studies  suggest  excellent  sen-
sitivity,  with  the  initial  image,  intermediate  images  after  a
few  courses  of  chemotherapy  and  imaging  after  autologous
transplantation  having  prognostic  value  for  survival.
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